Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

IFRS 17 Reporting Update
Fresh analysis from Fitch considers the current state of IFRS 17 reporting, revealing how close – or not – the standard has come to its original objec
Tracking risk, people and AI predictions 5 years after COVID
As working from home appears here to stay, effective leaders take a balanced and thoughtful approach to support employee wellbeing and organizational
Two thirds of employers embrace responsible pensions
Scottish Widows has revealed that more than two-thirds (69%) of employers in the UK now offer a responsibly invested company pension* - but less than

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.